[关键词]
[摘要]
泊马度胺(pomalidomide)为高效的第三代免疫调节剂(immunomodulatory drug,IMiD),其药理机制类似第一代IMiD沙利度胺,但较后者具有更强的体内外抗血管新生、抗肿瘤、抗炎症及抗骨髓瘤作用,且不良反应相对较少,患者口服耐受性良好。2013年2月,泊马度胺已获美国FDA批准用于复发/难治多发性骨髓瘤(multiple myeloma,MM)患者。本文重点就泊马度胺治疗复发/难治MM、骨髓纤维化、免疫球蛋白轻链型淀粉样变性(immunoglobulin light-chain amyloidosis,AL)、小细胞肺癌及其他晚期实体肿瘤的临床转化现状作一讨论。
[Key word]
[Abstract]
Pomalidomide is a highly potent third-generation immunomodulatory drug (IMiD), with pharmacologic properties similar to those of the first-generation drug thalidomide. However, compared with thalidomide, pomalidomide has stronger antiangiogenic, antineoplastic, and anti-inflammatory, and anti-myeloma activities in vitro and in vivo, with less side effects and better oral tolerance. In February, 2013, pomalidomide has been approved by the U.S. Food and Drug Administration for use in the treatment of relapsed and refractory multiple myeloma (MM). This review will focus on the recent advances on the translation of pomalidomide from bench to bedside as a therapeutic agent for relapsed and refractory multiple myeloma, myelofibrosis, immunoglobulin light-chain amyloidosis (AL), small cell lung cancer (SCLC), and other advanced solid tumors.
[中图分类号]
[基金项目]